VERA Company Profile and Key Details

Vera Therapeutics, Inc. (NASDAQ:VERA) closed at $54.09 USD, gaining $2.87 (5.59%) from the previous close of $51.22. The stock is currently trading near its 52-week high $18.53 and $54.57. With a market capitalization of about $3.46 billion, Vera Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 1.59 million shares, volume is running light vs its 52-week average. Headquartered in Brisbane, CA, Vera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marshall W. Fordyce, the company employs approximately 152 people and listed since May 14, 2021. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States.

Vera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.69. This means the shares are trading above this model’s fair value.

Vera Therapeutics, Inc. has 63.82 million shares outstanding. The public float is 42.92 million shares, elevated short interest at 15.31% of float. This equals 8.48 million shares. The short ratio is 5.0 days. Institutional investors hold 114.41% of the float. Insiders own 3.96%. COMMODORE CAPITAL LP holds 4.40 million shares, Sofinnova Venture Partners X, L.P. has 3.47 million shares and Carlyle Genesis UK LLC has 2.96 million shares. Over the past six months, insider transactions show net selling. They sold 48.86 thousand shares across 5 transactions.

VERA has shown sold momentum, gaining 11.3% over the past week and 100.16% over the past quarter, though year-to-date performance is up 21.12%. Short-term trend indicators are bearishly aligned (SMA20 23.72%, SMA50 51.43%, SMA200 95.49%). The stock’s 14-day RSI is 78.61 (overbought), while the ATR of 2.88 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 0.06% below its high and over 176.42% above its low. Average 10-day trading volume of 1.88 million shares is slightly above the 3-month average of 1.55 million, indicating heightened recent market interest.

Vera Therapeutics, Inc. generated EPS of -$3.99 over the past year. Five-year average earnings growth is 4.49%. Wall Street analysts project EPS growth of -1.16% annually over the next five years. The latest quarter delivered EPS of -$1.26. The next quarter is forecast at -$1.28. Next year's EPS is expected at -$1.12. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $99.00 to $33.00. The high target offers 93.28% upside. The low target suggests -35.57% downside. The mean target is $68.00. This offers 32.76% upside. Vera Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 5.0%. The prior quarter beat by 46.34%. Over the last six quarters, Apple has recorded several small beats. These include 6.9% in August 08, 2024.

Our AI price prediction model suggests that Vera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 22.24%, with price expected at $62.61 by January 02, 2026, within a range of $60.00 to $65.12 3-Month Outlook: Projected fall of -31.61%, reaching $35.03 by March 19, 2026, with a range of $32.09 to $37.78. 1-Year Outlook: Projected gain of 16.36%, with price at $59.60 by December 18, 2026, within a range of $54.54 to $62.91.

Vera Therapeutics, Inc. (NASDAQ:VERA) shares are up 21.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -14.97. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $56.57, suggesting 10.45% upside. Our AI forecast model points to short-term strength (22.24% over two weeks), a medium-term fall (-31.61% over three months), and a longer-term gain (16.36% over one year), with expected trading ranges indicating moderate volatility.

Vera Therapeutics, Inc. trades at a P/E ratio of -14.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.98 trading at moderately above to book value. The P/FCF stands at -15.49, also below market averages.